Why the study?
Good adherence to treatment is important for optimal control of arterial hypertension, but non-compliance remains a frequent problem.
What is the rate of adherence to pharmacological treatment and what factors are associated with non-compliance in patients with arterial hypertension in a Colombian university hospital?
What is the rate of adherence to pharmacological treatment and what factors are associated with non-compliance in patients with arterial hypertension in a Colombian university hospital?
A high rate of non-adherence (86%) to antihypertensive treatment was observed in a Colombian university hospital, primarily driven by health system barriers such as failure to supply medications.
Answers are grounded in this paper and cite their sources.
Supply failures drive most non-adherence here; leaves open whether targeted policies improve outcomes in similar settings.
Background: Arterial hypertension is one of the most prevalent who did not modifiable risk factors for cardiovascular disease. For an optimal control of this disease, it is important that patients have a good adherence to treatment, however, non compliance with treatment is still a frequent problem. Purpose: To characterize sociodemographically adherence to pharmacological treatment and identify the factors associated with therapeutic non-compliance in patients with arterial hypertension attending in a university hospital of Colombia. Methodology: This was an observational, descriptive, cross-sectional study. The entire population with a diagnosis of arterial hypertension who received care between April 1 and May 31, 2021 was included. The Morisky scale (MMAS-8) was used to assess adherence to pharmacological treatment. Results: 400 patients were included, of wich 56% were men. 14% of the patients were adherent to pharmacological treatment versus 86% who did not. The most frequently cause of non-adherence was the failure of the health insurers to supply medicines (49%). Conclusion: Non- adherence to pharmacological treatment remains a major barrier to achieving adequate control of chronic diseases.
No takes yet. Share an insight, caveat, or question.
Barón et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: